Clinical trial
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
NCT00221312 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00221312 |
|---|---|
| Title | Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss |
| Official title | Alendronate to Prevent Perimenopausal Transition Bone Loss |
| Lead sponsor | University of California, San Francisco, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Perimenopausal Bone Loss |
| Intervention type | Drug |
| Interventions | Fosamax |
| Enrollment | 48 |
| Start date | May 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | May 8, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: